Skip to main content

Talk Bio

Search This Blog

Yarrow begins trading as it advances Graves’ disease and thyroid eye disease program

on July 28, 2026

Get link
Facebook
X
Pinterest
Email
Other Apps

Yarrow Bioscience has completed a reverse merger with VYNE Therapeutics and its shares began trading on the Nasdaq under the ticker YARW on July 28, 2026, as it advances YB-101, an anti-TSHR antibody targeting Graves’ disease and thyroid eye disease.

The FDA has approved Otsuka Pharmaceutical's once-daily extended-release capsule SIMTRIYO (centanafadine), a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI), for the treatment of ADHD in adults and pediatric patients aged 6 years and older weighing at least 20 kg; the drug is expected to launch later in 2026 after DEA scheduling.

Sources:

Otsuka Receives FDA Approval for First-in-Class ...

FDA Approves Otsuka's SIMTRIYO: First New ADHD ...

Yarrow completes reverse merger with VYNE, enters ...

Otsuka's ADHD approval opens up new drug class with ...

FDA approves Simtriyo (centanafadine), a 'first of its kind' ...

Yarrow blooms with $1.37B autoimmune thyroid disease deal

Yarrow Bioscience完成与VYNE合并，Graves病药物YB-101启动II期临床

Vyne Therapeutics publishes investor presentation on Yarrow ...

Centanafadine - New ADHD Medication in 2026

VYNE and Yarrow agree merger to advance YB-101

Jack Shuang Hou's Post - LinkedIn

M&A Announcement summary - VYNE Therapeutics - Quartr

VYNE Therapeutics: A New Chapter in Autoimmune Disease with ...

VYNE shares surge 90.51% premarket after merger with Yarrow and ...

anti-TSHR centanafadine Drug Enforcement Administration NDSRI Otsuka reverse merger SIMTRIYO Thyroid associated opthalmopathies United States Food and Drug Administration Vyne yarrow flower extract YARW YB-101

Get link
Facebook
X
Pinterest
Email
Other Apps

Popular Posts

Rivus Pharmaceuticals Appoints Jorge Bartolome as Chief Executive Officer

Rivus Pharmaceuticals announced on February 25, 2026, the appointment of Jorge Bartolome as Chief Executive Officer and Board member, succeeding co-founder Allen Cunningham who transitions to Chief Operating Officer. 1 2 Jorge Bartolome brings over 25 years of experience, including CEO of AreteiaTx, President of Janssen Canada, and senior roles at GSK generating $8 billion in sales. 1 2 Rivus focuses on oral therapies for MASH, obesity, and cardiometabolic diseases, with lead candidate HU6 (oral mitochondrial uncoupler) succeeding in three Phase 2 trials. 1 2 2026 plans include advancing HU6 in the AMPLIFY Phase 2 trial for MASH and initiating first clinical trial for RV-8451, an oral muscle-preserving GLP-1 for obesity. 1 2 Ian F. Smith, Co-Chair of the Board, highlighted Bartolome's expertise in late-stage development and commercialization as ideal for Rivus' growth. 1 2 Sources: 1. https://www.globenewswire.com/news-release/2026/02/25/3244576/0/en/Rivus-Pharmaceu...

OKYO Pharma Appoints Flavio Mantelli, MD, PhD as Chief Medical Officer

OKYO Pharma announced on February 10, 2026, the appointment of Flavio Mantelli, MD, PhD, as Chief Medical Officer to lead clinical and regulatory strategy for urcosimod in neuropathic corneal pain (NCP). Dr. Mantelli previously served as CMO at Dompé, where he led the clinical development, FDA approval, and global strategy for Oxervate®, a blockbuster orphan drug with over $1 billion in sales in 2024. Urcosimod has FDA Fast Track designation for NCP, with a planned ~150-subject Phase 2b/3 multiple-dose study expected to start in H1 2026. This appointment follows the recent hiring of CEO Robert Dempsey and strengthens OKYO's ophthalmology leadership team. OKYO Pharma shares rose 10.80% intraday following the announcement. Sources:

KOL Bulletin: Brilaroxazine's Potential Differentiation on EPS Over Risperidone in Schizophrenia

A leading US KOL states that brilaroxazine shows placebo-like extrapyramidal symptoms (EPS) at week 4, potentially differentiating it from risperidone which cannot achieve this 1 . Reviva plans to initiate the RECOVER-2 Phase 3 trial for brilaroxazine in schizophrenia in H1 2026 following FDA recommendation for additional efficacy and safety data 2 . Brilaroxazine demonstrates broad-spectrum efficacy across schizophrenia symptom domains, including negative symptoms, with a well-tolerated safety profile in over 900 subjects 2 4 . Phase 3 RECOVER trial data shows low EPS and akathisia, mild weight gain (1.52 kg pooled), reductions in prolactin levels, and improvements in sexual function over 1 year 4 . New publication highlights speech latency as an objective vocal biomarker for brilaroxazine's effect on negative symptoms, reinforcing efficacy 3 5 . Sources: 1. https://firstwordhealthtech.com 2. https://www.biospace.com/press-releases/reviva-announces-regulatory-update-...

Powered by Blogger

X-Data LLC